GeoVax Set to Disclose Q1 2025 Financial Results and Provide Corporate Update
Clinical-stage biotechnology company GeoVax Labs will release its first quarter 2025 financial results and host a conference call, offering insights into its COVID-19 vaccine development and oncology programs. The announcement provides stakeholders an opportunity to learn about the company's recent progress and strategic direction.
GeoVax Labs, Inc., a clinical-stage biotechnology company focused on developing vaccines and immunotherapies, will report its first quarter 2025 financial results on May 1, 2025, after U.S. market close. The company will follow the financial disclosure with a conference call and webcast at 4:30 p.m. ET, providing stakeholders an opportunity to gain insights into its ongoing research and development efforts.
The conference call will highlight the company's key clinical programs, including its next-generation COVID-19 vaccine GEO-CM04S1, which is currently undergoing three Phase 2 clinical trials. These trials are exploring the vaccine's potential for immunocompromised patients, as a booster for chronic lymphocytic leukemia patients, and as a more robust booster for individuals previously vaccinated with mRNA vaccines.
In addition to its COVID-19 research, GeoVax will likely discuss its oncology program, which recently completed a Phase 1/2 clinical trial for Gedeptin®, a gene-directed therapy targeting advanced head and neck cancers. The company is also developing GEO-MVA, a vaccine aimed at addressing Mpox and smallpox.
The upcoming conference call represents a critical moment for investors and healthcare professionals to understand GeoVax's strategic direction and potential contributions to medical research. By providing detailed updates on its clinical trials and financial performance, the company offers transparency about its innovative approaches to vaccine development and cancer therapy.